VYVANSE® – new ADHD treatment option – now available in Canada
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
Original Source of VYVANSE® – new ADHD treatment option – now available in Canada
